US Politics
The Regeneron Deal: A Symptom of Our Broken, Opaque Approach to Drug Pricing
President Donald Trump has announced a final deal with drugmaker Regeneron, part of a series of agreements to lower U.S. drug prices through Medicaid discounts and direct sales initiatives like TrumpRx. While any action to reduce the crushing burden of prescription drug costs is a moral imperative, the secretive nature of these deals and their use as political tools, rather than codified law, dangerously undermines the transparent and lasting solutions Americans desperately need for true healthcare liberty.
